31 selected records with a cited source date in 2009. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.
The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PubMed lists PMID 17156777 in Experimental cell research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-11-07 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide.
PubMed lists PMID 2885699 in Lijecnicki vjesnik as Clinical Trial, Comparative Study, English Abstract, Journal Article, with publication-date metadata of 1987 Feb-Mar (source-text precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for NDA 021919 with status AP dated 2009-10-30, and names exenatide synthetic among the application record's active ingredients.
PeptideScanner retained PubMed bibliographic metadata for PMID 19864727 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19864763 at 2026-07-30T22:27:39.979Z. PubMed recorded a metadata revision date of 2009-10-29 and an Entrez history date of 2009-10-30. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00859534 at 2026-07-30T22:26:45.018Z. Its registry update date was 2009-09-15, and PeptideScanner's reviewed identity mapping was afamelanotide.
PubMed lists PMID 19733082 in Trends in biochemical sciences as Journal Article, Review, with publication-date metadata of 2009-09-03 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00974272 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-09-10, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 19663134 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Case Reports, Letter, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 19588557 at 2026-07-30T22:27:39.924Z. PubMed recorded a metadata revision date of 2009-08-04 and an Entrez history date of 2009-07-10. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
The official Drugs@FDA dataset lists original submission 1 for ANDA 076979 with status AP dated 2009-06-08, and names calcitonin salmon among the application record's active ingredients.
The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
PeptideScanner retained PubMed bibliographic metadata for PMID 20641226 at 2026-07-30T22:27:39.988Z. PubMed recorded a metadata revision date of 2009-06-05 and an Entrez history date of 2009-06-05. PeptideScanner associated this retained record with the identity slug octreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00434772 at 2026-07-30T22:26:45.006Z. Its registry update date was 2009-05-28, and PeptideScanner's reviewed identity mapping was glucagon.
PubMed lists PMID 19453267 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2009-06 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00902655 at 2026-11-16T01:33:21.554Z. Its registry update date was 2009-05-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained PubMed bibliographic metadata for PMID 19441725 at 2026-07-30T22:27:39.905Z. PubMed recorded a metadata revision date of 2009-05-15 and an Entrez history date of 2009-05-16. PeptideScanner associated this retained record with the identity slug semax. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00250991 at 2026-11-15T21:59:29.646Z. Its registry update date was 2009-05-08, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00817271 at 2026-07-30T22:26:45.011Z. Its registry update date was 2009-05-07, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide.
The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 078885 with status AP dated 2009-03-09, and names leuprolide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00565097 at 2026-07-30T22:26:45.013Z. Its registry update date was 2009-02-17, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00448461 at 2026-11-15T21:58:19.888Z. Its registry update date was 2009-02-10, and PeptideScanner's reviewed identity mapping was bivalirudin.